A new study reports that hybrid immunity induced by vaccination and previous infection induces SARS-CoV-2-specific tissue-resident T-cells in the nasal cavity.
Researchers explored how effectively nanotechnology-based novel and potential vaccines, drugs, and monoclonal antibodies could combat the current and yet to emerge SARS-CoV-2 variants.
An in-depth review article describing coronavirus disease 2019 (COVID-19)-related coagulopathy has recently been published in the journal Nature Reviews Immunology.